Amphastar Pharmaceuticals, Inc. (AMPH) — Fair Value Analysis

Base-case fair value (P50): $19.87 · Current price: $20.91 · Verdict: Fairly Valued

The Verdict on AMPH

Our Monte Carlo simulations indicate that AMPHASTAR PHARMACEUTICALS INC (AMPH) is currently Fairly Valued. Trading at $20.91, AMPH sits marginally above its median fair value (P50) of $19.87, implying an -5.0% differential. This narrow range suggests that the market price largely aligns with the intrinsic value derived from thousands of forward-looking scenarios. For investors considering AMPH at $20.91, this fair valuation signals a balanced risk-reward profile, where significant short-term mispricing is not apparent.

How AMPH stacks up against Healthcare

Within the Healthcare sector, AMPH exhibits an average quality tier, reflecting its operational and financial health relative to its peers. While the sector as a whole often presents diverse valuation opportunities, AMPH's current trading at $20.91 and its median fair value of $19.87 place it squarely in the "fairly valued" category. This average quality tier, coupled with a minimal -5.0% gap, suggests that AMPH is neither a distressed asset nor a clear bargain when compared to its industry counterparts, warranting careful consideration for portfolio allocation.

What this means for investors

Investors monitoring AMPH should note that the current price of $20.91 is closely tracking its P50 fair value of $19.87, with a modest -5.0%. This indicates that current market expectations largely align with the probabilistic outcomes generated by our models, leaving little room for immediate alpha solely based on a clear valuation gap. While there isn't a strong signal for undervaluation or overvaluation, a detailed understanding of the full bear case and bull case scenarios is crucial. For a comprehensive view of AMPH's fair value distribution, including the full bear and bull targets, and to track its fair value as new fundamentals are released, sign up for a free FairCurve account.